Multiple analysts predict blockbuster sales revenue for BioMarin Pharmaceutical Inc.’s Voxzogo (vosoritide), the first drug approved in the US for achondroplasia, but company executives guided to a slow ramp-up due to the complications of being first to market in a rare disease during an investor call.
Voxzogo, a C-type natriuretic peptide (CNP) analog injected daily, obtained accelerated approval from the US Food and Drug Administration on 19 November. The drug will have a daily wholesale acquisition cost of $899 per vial, which BioMarin said should net out to about $240,000 per year after discounts
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?